What is an Investigator's Brochure (IB)? A GCP Guide

The Investigator’s Brochure (IB) is a pivotal clinical-trial document that compiles clinical and nonclinical data on an investigational medicinal product relevant to studies in humans. For EU medical-device clinical investigations within the MDR scope, a device-specific IB contains the available clinical and nonclinical information relevant to the investigation. It compiles preclinical (laboratory and animal) studies alongside any prior clinical experience, providing investigators, ethics committees, and regulators with the evidence needed to assess risk–benefit and guide study conduct. As a part of Good Clinical Practice (GCP) and regulatory submissions (e.g. IND/CTA), the IB ensures that trials are scientifically sound and ethical. In practice, a well-prepared IB supports safe trial design, informed investigator decisions, and regulatory compliance (^[1]) (^[2]). Conversely, incomplete or outdated IBs can undermine independent risk assessment, compromise participant safety, and result in regulatory findings (^[3]) (^[4]).

This report provides an in-depth examination of the IB: its origins, regulatory framework, content requirements, and role in clinical research; as well as analysis of how it is prepared, reviewed, and used. We discuss IB structure and required content (e.g. summaries of pharmacology, toxicology, human data, and guidance for investigators) as defined by ICH GCP, FDA and EMA regulations (^[1]) (^[5]). Historical and real-world case studies (e.g. the TGN1412 and BIA10-2474 trials) illustrate the IB’s importance in human trial safety and lessons learned from failures. We review empirical studies and expert commentary highlighting deficiencies in many IBs (e.g. poor reporting of preclinical methodology and lack of negative results) that limit independent evaluation (^[3]) (^[6]). Conversely, we present strategies and tools (such as IB-DeRisk, improved templates, AI-powered IB platforms, and the now-finalized ICH E6(R3) guideline) aimed at improving IB quality and clarity (^[7]) (^[8]).

Data and statistics are incorporated where available: for example, a 2020 analysis of 46 phase I/II IBs (777 preclinical studies) found that fewer than 1% of studies reported basic validity measures (randomization, blinding) and only 5% referenced published sources (^[9]). Such findings have prompted calls for better transparency in IBs (^[3]) (^[8]). Regulatory and empirical claims in this report should be assessed against the cited underlying sources. The conclusion synthesizes key points and discusses future directions, such as more interactive IB formats, risk-based content emphasis, and the evolving regulatory landscape. The overall message is clear: the Investigator’s Brochure is essential for safe and ethical clinical trials, and its meticulous preparation and use directly support participant protection and research integrity.

Interventional clinical trials may evaluate an investigational product (IP), such as a drug, biologic, or device, in human participants. Their objectives and designs vary and may assess safety, efficacy, pharmacokinetics, pharmacodynamics, or other study-specific outcomes. Before exposing people to an IP, investigators need complete information on what is already known about it. The Investigator’s Brochure (IB) provides this information: ICH E6(R3) defines it as a compilation of clinical and nonclinical data on investigational product(s) relevant to their study in human participants (^[10]). In essence, the IB is a centralized, continuously updated dossier that conveys the totality of knowledge about the product’s chemistry, pharmacology, toxicology, pharmacokinetics, prior human experience, and known or anticipated risks. Its purpose is to inform and guide investigators and their teams, enabling them to conduct the trial properly and protect participant safety (^[1]) (^[2]).

Historically, the IB concept emerged from ethical and regulatory imperatives to safeguard human subjects in research. Early drug development lacked standardized information transfer, but by the late 20th century regulators (e.g. FDA and EMA) codified IB requirements. In the United States, 21 CFR §312.23 (IND content) mandated including an IB with preclinical summaries for drug trials (^[5]). In Europe and elsewhere, the International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use established uniform GCP guidelines. ICH GCP E6 (first issued in 1996, updated R2 in 2016, and most recently R3 finalized in January 2025) explicitly details IB content and preparation, making the IB an international standard for trial applications (^[1]) (^[5]). Regulatory frameworks (such as FDA’s IND regulations and the EMA’s Clinical Trials Regulation) require a valid IB as part of the trial application, reflecting its foundational role in review and oversight (^[5]) (^[11]).

In practice, the IB must be written clearly, concisely, and objectively, without promotional bias, so that clinicians and ethics committees can make an “unbiased risk–benefit assessment” of a proposed trial (^[1]) (^[2]). It typically runs hundreds of pages for a novel product. The challenge is to balance completeness with clarity: investigators must see all relevant findings (even negative results) but also interpret them quickly in planning trials. As such, the IB is often considered the single most comprehensive document on the investigational product, serving investigators, institutional review boards (IRBs)/ethics committees, and regulatory authorities alike (^[1]) (^[12]). This report will explore the IB’s definition, structure, regulatory context, and practical importance, as well as analyze how deficiencies in IB content can pose risks and how those can be addressed.

The IB’s role and contents are defined by regulations and guidances from multiple authorities:

• FDA (United States): Under 21 CFR §312.23(a)(5), sponsors must submit an IB (if required) as part of an Investigational New Drug (IND) application. The regulation specifies that the IB include: (i) a brief description of the drug substance and formulation; (ii) a summary of pharmacological and toxicological effects in animals and, to the extent known, humans; (iii) summary of pharmacokinetics and disposition in animals and humans; (iv) summary of human safety and effectiveness data from prior trials (with reprints appended if useful); and (v) description of possible risks/side effects based on prior experience with the drug or related drugs, and monitoring/precautions to take (^[5]). These requirements broadly align with ICH guidance for drug products. Under 21 CFR §312.55, a sponsor (other than a sponsor-investigator) must provide each participating clinical investigator with an IB before the investigation begins and keep investigators informed of important new observations, particularly regarding adverse effects and safe use. Sections 312.57 and 312.60–312.62 instead address sponsor recordkeeping and investigator responsibilities, drug control, and investigator records. In December 2025, FDA finalized guidance on "Sponsor Responsibilities — Safety Reporting Requirements and Safety Assessment for IND and BA/BE Studies," further clarifying how IB safety information must be maintained and communicated (^[13]). The FDA Modernization Act 2.0, enacted in 2022, amended the statutory language for investigational new drugs to allow nonclinical tests, rather than prescribing animal tests. It does not eliminate the need for evidence adequate for the particular investigational product; the appropriate nonclinical evidence remains case-specific.

• ICH GCP (International): The ICH E6 guideline (Good Clinical Practice) has long addressed the IB. Under the previous E6(R2) (2016), Section 7 was devoted to the IB. The successor, ICH E6(R3), was finalized on January 6, 2025, and restructures the GCP framework into core principles and annexes. IB content requirements now reside in Appendix A of E6(R3) (^[14]). The guideline defines the IB as ”a compilation of the clinical and nonclinical data on the investigational product(s)” needed for human studies (^[15]). It emphasizes that the IB should facilitate the investigator’s understanding of the study’s rationale, dosing, administration, and safety monitoring, and enable an unbiased risk–benefit assessment (^[1]). The guideline also stipulates that the IB be reviewed at least annually or whenever significant new information arises, and that it be approved by medically qualified personnel and those who generated the data (^[1]) (^[2]). Regional adoption is underway: EMA adopted E6(R3) effective July 2025, FDA published its final guidance in September 2025, and Health Canada begins applying it April 2026.

• European Union: The EU’s Clinical Trials Regulation 536/2014 requires submission of an IB (or equivalent) with a clinical trial application for any investigational medicinal product. The Clinical Trials Information System (CTIS) completed its full transition on January 31, 2025, migrating all ongoing trials from the old Directive. CTIS was designated a WHO Primary Registry in April 2025, further harmonizing trial data internationally. Similarly, post-MDR (Medical Device Regulation 2017/745), an IB (device) containing relevant clinical and nonclinical information is required for investigational devices (^[16]). Notably, the MDCG 2024-5 guidance (April 2024) provides a detailed checklist for device IB content under EU MDR 2017/745, aligned with ISO 14155:2020 (^[17]). National competent authorities (NCAs) in the EU expect an up-to-date IB, which is reviewed as part of the trial authorization process (^[11]).

• Other Regions: Many countries have aligned with ICH or have their own provisions referencing IB requirements. For example, Brazil’s clinical trial regulations adopt ICH E6 requirements for IB content (^[18]). WHO and other bodies also expect an IB for investigational drugs. In sum, globally, the IB is a mandated component of trial oversight, reflecting universal recognition of its importance.

Regulatory guidance highlights several core principles about the IB:

• Comprehensive yet focused content: ICH E6(R2) outlines specific sections that an IB typically contains (see Table 1). These include summaries of chemistry/pharmaceutics, nonclinical pharmacology/toxicology, human pharmacokinetics/effects, and a final “Summary of Data and Guidance for the Investigator” (^[19]) (^[20]). The content must be presented in a concise, balanced, non-promotional manner (^[1]) (^[2]). As one guideline puts it, the IB should enable a clinician to “make his/her own unbiased risk–benefit assessment” (^[1]).

• Update and distribution: ICH GCP and FDA require that IBs be kept current. ICH explicitly calls for at least annual review and immediate issuance of critical new information (^[21]). Sponsors are responsible for ensuring current IB versions are available to investigators, and investigators must provide them to IRBs/ECs (^[22]). The EUPATI patient-resource also notes that regulatory authorities (EMA and NCAs) review each IB update for accuracy and completeness (^[11]). In practical terms, any “significant new data” (e.g. adverse events, new trial results) triggers an IB revision.

• Confidentiality and ownership: The IB is a sponsor-controlled document. It typically includes a confidentiality statement, restricting its use to the investigative team and ethics committees (^[23]) (^[24]). Because it contains proprietary data, the IB itself is usually not made public; however, relevant summary data eventually appear in publications and registries. Regulatory agencies inspect IB compliance but generally do not publish IB content.

• Medical and technical review: To ensure validity, regulatory guidance advises that a medically qualified individual participate in drafting or reviewing the IB content. For example, ICH recommends that a medically qualified person help edit the IB to facilitate clinician understanding (^[25]). The recent AGAH forum consensus echoed this: IBs should be signed (endorsed) by a sponsor scientist responsible for pharmacology/toxicology content (^[26]). Multidisciplinary approvals (clinical, lab, regulatory) are expected.

• Reference Safety Information (RSI): The IB typically contains a section summarizing known adverse reactions (often in an appendix), known as RSI. ICH E6(R3), finalized in January 2025, formalized that the RSI should list adverse reactions with frequency and nature, serving as the basis for determining whether a new SAE is “unexpected.” The IB content requirements are now detailed in Appendix A of E6(R3), which also references ICH E2F for RSI standards (^[14]).

Overall, the IB is framed in guidance as essential background for safe trial conduct. Its comprehensive content is mandated by regulators, while its clarity and currency are emphasized by consensus experts (^[1]) (^[27]).

The Investigator’s Brochure is structured into standard sections to organize the wealth of data on the product. While exact formats can vary, guidance (ICH E6) and best practices suggest the following outline (see Table 1). Each section is referenced to the trial’s development stage and provides specific information:

Table 1. Typical Investigator’s Brochure Structure and Content (per ICH E6 GCP; now Appendix A in E6(R3))

As an example entry, ICH E6 recommends that the “Summary of Data and Guidance” section provides “an overall discussion of the nonclinical and clinical data” and summarizes significant chemical, pharmacological, and toxicological findings (^[19]). The IB therefore moves from high-level summary into detailed data and back into a synthesis with action items for the investigator. In table format, IBs often use both narrative text and charts/plots to make the voluminous information accessible.

Importantly, every factual claim in the IB (e.g. animal LD50, human PK values) is traceable to a reference. Sponsors frequently use “line listings” of study results or tabulated comparison of dose levels vs effects. The content reflects the development stage: an IB for a Phase I trial (first-in-human) will emphasize preclinical toxicology and starting-dose rationale, whereas an IB for later phases will incorporate Phase I trial results and more extensive human data (^[21]) (^[37]).

The IB is compiled and maintained by the sponsor or sponsor-investigator. Authors typically include regulatory affairs professionals, pharmacologists/toxicologists, and medical writers, under the oversight of a medically qualified individual. ICH E6 suggests that a medically qualified person should “generally participate in the editing of an IB,” and that each discipline contributing data should approve the content (^[38]). Recent expert forums have echoed that recommendation: for instance, participants agreed the IB should be signed by the sponsor’s scientist responsible for pharmacology/toxicology content, ensuring accountability (^[26]). In practice, each IB version goes through rigorous internal review (safety/pharmacology teams, clinical leads) before release.

Professional third-party CROs or consultants often assist sponsors, especially smaller firms, in drafting IBs. Templates and historical IBs may be used as starting points, but content must be carefully updated to the current product. Key attributes of quality authorship include clarity (avoidance of overly technical jargon for clinical sections), completeness (inclusion of all relevant studies), and balance (reporting both positive and negative data). As one consensus concluded: “Non-clinical pharmacology studies with negative outcomes should be reported in the IB in order to avoid assessment bias” (^[8]). Incomplete reporting can mislead investigators – thus thoroughness is emphasized by regulators and ethicists.

An IB is a living document. ICH GCP requires that it be reviewed “at least annually” and revised as needed to incorporate new information (^[21]). In reality, many sponsors update the IB more frequently if warranted (e.g. after a clinical trial completion or a regulatory safety alert). Each published IB includes a version identifier (edition number, date, superseded version reference) as recommended by ICH (^[39]). Change histories are often documented to track modifications between versions.

Regulators and IRBs expect investigators to reference the most current IB. Outdated versions can result in serious GCP inspection findings. For example, if an investigator administers doses or implements procedures based on stale information, participant safety could be compromised. Therefore, sponsors distribute every IB update (either in printed/electronic form or via an electronic document system) and investigators must acknowledge receipt. The ethical review boards also often request the current IB when reviewing ongoing trials or approving amendments, since it encapsulates recent safety data.

Technological trends are introducing “e-IBs” (electronic IBs) and content databases, allowing easier global distribution and integration with eTMF (electronic Trial Master File) systems. Tools like IB-DeRisk (discussed below) enable dynamic visualization of IB data. Electronic document systems may support controlled distribution and version management, but sponsors remain responsible for the accuracy, review, approval, and retention of each IB revision. In the future, IBs may be modular and digital, potentially improving real-time updates. Regardless of format, regulatory compliance still demands that each revision pass through signature and archiving controls (per GCP documentation standards).

Given its dynamic nature, rigorous version control is critical. Every IB version is uniquely identified, and outdated editions are clearly marked as superseded. Audit trails in e-systems record who authored and approved each change. Sponsors implement Standard Operating Procedures (SOPs) for IB management to ensure ALCOA+ integrity (Attributable, Legible, Contemporaneous, Original, Accurate) (^[40]). Missing or misfiled IB versions in the TMF (e.g. Trial Master File) can trigger regulatory citations during inspections (^[40]).

IB confidentiality is equally important. By strict policy, the IB is not disclosed outside the research context. It is distributed only to trial investigators, IRBs/IECs, and regulators. Some IBs carry a cover page stamping “Confidential – For Trial Use Only” and explicitly forbid external sharing (^[23]) (^[24]). This protects proprietary data (often from sensitive preclinical studies) while still allowing necessary oversight. A separate sponsor-authored “Investigator Packet” or Informed Consent materials translate IB data into patient-friendly language, but the detailed IB itself remains internal.

Participant safety is the foremost concern in any trial. In early-phase studies, where little human data exist, risks and uncertainties are evaluated primarily from the IB. As one regulatory commentary explains: “During the early stages of development, clinical experience with the IMP is either lacking or sparse, leaving assessment of risk dependent on non-clinical pharmacology, safety and toxicology data... Those involved in design, approval and conduct of clinical trials are required to base decisions on all available data — with the Investigator’s Brochure being the pivotal document where these data can be found” (^[27]). In other words, the IB is the key source for understanding potential hazards (and benefits) when planning a trial.

The IB’s role is to present that information so investigators can make their own unbiased assessment of whether a trial is appropriate (^[1]) (^[2]). This includes determining safe starting doses, dose escalation schemes, monitoring plans, and specifying contraindications. For example, comprehensive animal toxicity data in the IB inform the selection of a Maximum Recommended Starting Dose (often via MABEL or NOAEL approaches (^[41]) (^[42])). Similarly, any adverse events seen in prior human use (in other trials or “expanded access” programs) must be described so investigators can anticipate them and decide how to detect or prevent harm.

A well-constructed IB directly supports informed consent as well: what investigators learn from the IB flows into the information given to trial participants (via the consent form). Although participants do not receive the IB, their consent is based on the risks/benefits drawn from it. Thus, an accurate IB underpins both investigator and patient understanding of trial risks.

Regulators and IRBs require the IB to certify that the trial has a sound scientific rationale and that risks have been appropriately evaluated. For instance, in FDA inspections of clinical trials, examiners routinely check whether the investigator has the current IB and whether it has been used to guide the study. Any significant safety issue discovered during a trial (e.g. unexpected toxicity) generally leads the sponsor to issue an IB amendment so investigators are promptly informed and consent processes updated.

Ethically, the IB supports the Belmont Report’s principles of beneficence and justice by helping reviewers assess risks, benefits, and the fair selection of research participants (^[43]). Without a thorough IB, an IRB could not fully assess the trial’s risk–benefit balance. Indeed, as one author notes, the ethics of first-in-human trials “can only be conducted with supportive prospective risk–benefit assessment. This relies largely on preclinical animal studies ... reported in an IB to inform ethics review boards and regulatory authorities” (^[44]).

Beyond initial trial approval, the IB guides intra-trial clinical management. During conduct of the study, the IB is a reference for permissible dose adjustments, treatment of adverse events, and criteria for stopping or modifying the trial. Investigators are taught to consult the IB’s Summary of Data and Guidance before making critical decisions. The IB also often contains a recommended antidote or rescue therapy, if known (e.g. providing an antagonist in case of overdose). Thus, it is a dynamic reference manual throughout the trial.

In sum, why the IB matters can be distilled into three points:

1. Participant Safety – It conveys all known risks (and benefits) to prevent serious harm.
2. Investigator Empowerment – It equips clinicians with the scientific basis to manage the study responsibly, enabling informed dosing and monitoring.
3. Regulatory Requirement – It ensures compliance with ethical and legal standards, demonstrating due diligence by the sponsor.

Failure to provide an adequate IB can have concrete consequences. For example, if an investigator dose-escalates without knowledge of animal toxicity data, volunteers could suffer severe effects. Conversely, advancements in IB best practices directly improve trial outcomes; clearer IBs lead to more appropriate risk mitigation and smoother regulatory review.

While the IB’s importance is undisputed, studies have shown that many IBs fall short in practice. Researchers have analyzed actual IBs to assess how well they support independent evaluation of safety and efficacy.

A 2020 analysis in British Journal of Clinical Pharmacology examined 46 IBs (phase I/II trials) at a major German university from 2010–2016 (^[45]). Key findings included:

• Poor reporting of study design: In 777 animal safety studies cited, <1% reported using blinding, <1% reported randomization, and <1% reported sample size calculation (^[6]). Thus for almost all studies, basic validity measures were absent or unreported. Only 52% mentioned GLP compliance (which does not guarantee methodological rigor) and only 5% linked to any published data (^[6]).

• Limited reference to published literature: Because most data came from internal reports, IBs offered little transparency. With so few studies referenced to accessible publications, outside reviewers cannot easily verify or scrutinize the findings.

• Omission of negative findings: Many IBs failed to explicitly report animal studies with adverse or null results. Without these, readers might overestimate the safety/efficacy profile.

The study concluded that this “scarce reporting in IBs” makes it “almost impossible for investigators to critically evaluate the robustness of preclinical evidence of drug safety” (^[46]). A follow-up commentary stressed that the IB often lacks reliable data to assess study validity, urging sharing of all preclinical data and publication wherever possible (^[3]) (^[47]).

Other work has looked at efficacy data in IBs: a 2018 PLOS Biology article similarly found that preclinical efficacy studies in IBs were modest in number and often showed publication bias (i.e. unbalanced favoring positive results) (^[3]). The emerging consensus is that while IBs aggregate data, the quality and completeness of that reporting need improvement. Investigators and regulators may be receiving an “optimistic” or at least incomplete view of evidence, hindering truly meaningful risk assessment (^[3]) (^[26]).

On the other hand, case studies of IB use in crises highlight its role (see below). Analysis also shows where IBs succeeded: in many first-in-human trials, strong preclinical rationales (well-described in the IB) allowed safe progression in hundreds or thousands of subjects. For example, one meta-analysis found that non-oncology Phase I trials in healthy volunteers are remarkably safe: life-threatening events are rare (^[48]). While this indicates overall adequacy of preclinical evaluation, any time a serious event occurs unexpectedly, scrutiny often turns back to the IB for insight.

A qualitative AGAH consensus survey of risk specialists found that investigators and CROs see room for IB improvement. Respondents rated the “Summary of Data and Guidance” section as needing better readability and timeliness (^[49]). They recommended explicit sign-offs, change histories, and inclusion of all data (even negative) to avoid bias (^[26]). This reflects a broad professional desire to make IBs more useful.

Examining high-profile clinical incidents illuminates how the IB functions in reality – and why it matters when something goes wrong. Two notorious Phase I trials exemplify the IB’s role:

In March 2006, six healthy volunteers in London received the monoclonal antibody TGN1412 (a CD28 superagonist) and developed catastrophic “cytokine storm” reactions within hours (^[50]) (^[51]). Five required intensive care. Importantly, preclinical studies (dogs and non-human primates) had shown the drug to be safe at far higher doses (^[52]). The investigators, reviewing the IB at trial time, had been led to expect only minor immune activation.

Investigations after the incident revealed critical gaps:

• The IB’s preclinical pharmacology section emphasized that TGN1412 expanded T-cells without causing cytokines, based on standard lab assays (^[53]). However, these methods failed to predict the human immune response.
• The IB did not contain the now-famous insight that emerged later: the particular epitope engaged by TGN1412 in humans was different from that in animal models, a fact not appreciated pretrial.
• A subsequent detailed review (van Gerven et al., 2018) observed that “the IB … should enable investigators or regulators to independently assess the risk–benefit of the proposed trial but the size and complexity [of the IB] makes this difficult” (^[7]). In fact, the authors suggested that lack of clear data integration in the IB “may have contributed to the oversight in the trials with TGN1412” (^[51]).

In response, Europe tightened First-in-Human (FIH) trial guidelines, requiring sponsors to explicitly discuss uncertainty around predicted effects from the IB, and to consider mechanisms of action and species differences (^[50]) (^[51]). The TGN1412 event remains a stark example of how a limited IB dataset can precede disaster, underscoring regulators’ insistence on cautious dose selection and rigorous IB analysis for novel compounds.

A very similar scenario occurred in 2016 during Phase I trials of BIA 10-2474, a fatty acid amide hydrolase (FAAH) inhibitor developed by BIAL (Portugal). After only 5–6 days of 50 mg daily dosing in healthy volunteers, one participant died of brain haemorrhage and necrosis and several others suffered irreversible neurological damage (^[54]). Prior single-dose studies at lower levels showed no such issues, and animal studies (in rats, mice, dogs, monkeys) had revealed no significant neurotoxicity (^[55]).

Retrospective analysis of the IB from that trial highlighted issues:

• The published accounts note that no relevant signals appeared in any standard toxicity tests, and the IB focused on expected FAAH inhibition effects (^[55]). However, a more detailed inquest found that certain high-dose primate studies did show unexpected findings (e.g. brainstem effects in monkeys) that were not fully heeded (^[56]).
• One review remarks that the BIAL IB described its purpose rather than detailed pharmacology: initially it stated only general indications (enhancing endocannabinoid levels), without useful safety warnings (^[57]).
• After the incident, expert panels concluded that the IB had not anticipated off-target effects of BIA 10-2474 on other enzymes or systems (^[55]) (^[58]). The tragedy prompted regulatory changes (e.g. the EMA’s 2017 FIH guideline) similar to those after TGN1412.

Both TGN1412 and BIA 10-2474 cases demonstrate that severe toxicity can occur even with full compliance with IB-based risk assessments, but they also show that more robust IB analyses might flag “red flags”. For example, if dose-exposure relationships had been more critically charted or if negative or unexpected animal data had been emphasized in the IB, the investigators may have been warned earlier. These cases highlight the need for IBs to be crystal-clear about uncertainties. As one author bluntly states: IBs “remain remarkable” for their limitations, given that we hold human RCTs to high methodological standards while IBs often do not (^[59]).

A well-prepared IB can support careful, stepwise trial planning by presenting the available nonclinical and clinical information relevant to the protocol. It does not, by itself, establish that a particular dosing or enrolment approach is appropriate; those decisions must be justified by the protocol, the available evidence, and applicable regulatory requirements.

To illustrate differences in IB expectations across product types, Table 2 compares drug versus device Investigational Brochures, reflecting major regulatory frameworks.

Table 2. Investigator’s Brochure Requirements: Drug vs. Medical Device

(Data sources: FDA 21 CFR Part 312; ICH E6(R3); MDR 2017/745, Article 70 and Annex XV; and MDCG 2024-5.)

As Table 2 shows, for drug/biologic trials, the IB centers on pharmacological and toxicological profiles of the compound (reflecting drug development paradigms) (^[5]) (^[61]). By contrast, for device trials, an analogous “Investigational Device Brochure” focuses on device engineering, mechanical/in vivo test results, and existing clinical usage of similar devices (^[16]). Both forms of IB support investigator and ethics-review assessment, but their content and submission requirements depend on the product type and applicable jurisdiction. Under the EU MDR, the IB is part of the Annex XV documentation for clinical-investigation applications within the Regulation’s scope; other trials should follow the requirements of their applicable authority.

Empirical analyses of IBs have quantified key problems:

• Lack of methodological detail: As noted, almost no IB-reported studies described randomization or blinding (^[6]) (^[3]). This is far below expectations set by ARRIVE guidelines for animal studies or CONSORT for clinical trials. It suggests that IB readers cannot judge internal validity of the data.
• Selective reporting: Meta-research has found indications that IBs often omit negative or inconclusive results (^[3]). The AGAH forum recommended including all data to avoid “assessment bias” (^[8]).
• Limited public availability: Because most IB data come from proprietary reports, external researchers cannot verify the data at all. Case law on academic reproducibility underscores the risk: if foundational hazard claims in IBs are wrong or fraudulent, downstream trials may fail.

To improve IB transparency, scholars recommend:

• Publishing preclinical studies in peer-reviewed journals when feasible (^[64]). This subjects the data to external scrutiny and provides open references. However, IP concerns (trade secrets) can limit this, especially for early-stage biotech companies.
• Using integrative tools (like the IB-DeRisk described by van Gerven and Cohen) (^[7]). These allow data to be plotted (dose vs effect) enabling quick pattern recognition (e.g. safety margin between efficacious vs toxic doses). The goal is to present IB data “in a single page color-coded overview” to highlight therapeutic indexes and outliers (^[65]). Such visualization could mitigate the “size and complexity” issue noted by van Gerven: it “makes [the IB] difficult” to independently assess risk when buried in hundreds of pages (^[7]).

While systematic data on IB quality versus trial outcomes are sparse, several observations arise:

• A rigorously prepared, current IB can help reviewers locate the product rationale, available evidence, and proposed safety measures. Its effect on amendment frequency or review timelines will depend on the study, review body, and the completeness of the broader application.
• Conversely, inadequate IBs can trigger requests for information from ethics boards or regulators. For example, if the IB’s guidance section is vague or outdated, IRBs may require protocol revisions or extra safety monitoring, delaying trial start.
• The meta-risk of first-in-human trials remains low: a large analysis found the overall risk of death in non-oncology Phase I studies was approximately 0.16% (^[48]). This implies that for most drugs, the IB’s content (derived from animal data) is sufficiently preventive. Nonetheless, each death or SAE garners intense scrutiny, as seen with TGN1412 and BIA-2474, where IB limitations were implicated.

In statistics, one might note that of thousands of novel compounds tested, only a handful have had catastrophes traceable to unforeseen preclinical issues. However, regulatory prudence demands preparing for the extreme, and this has elevated the IB’s spotlight. Improving IB transparency and critical analysis can only facilitate better predictions and avoid surprises.

Based on guidelines and expert consensus, recommended approaches to make an IB effective include:

• Clarity and Readability: Use concise language, avoid excessive detail in summary sections, and highlight key information (e.g. via bullet points or tables). The AGAH forum emphasized the need for the Summary and Investigator Guidance sections to be readable and promptly highlight new data (^[49]).
• Balanced Reporting: Present both positive and negative results from studies to avoid bias. Explicitly note where important effects were absent.
• Traceability: Reference every data point to its source report or publication. A good IB lets investigators easily follow a finding back to detailed reports if needed.
• Timely Updates: Revise the IB promptly after each relevant study is completed. In practice, sponsors often update the IB concurrently with trial safety reports.
• Change History: Document version histories and last revision date on the cover page. Some organizations maintain an “IB change log” either within the IB or as a separate appendix.
• Engagement of Experts: Ensure that toxicologists, pharmacologists, and clinicians collaborate in drafting. For example, have a qualified physician review dosing and safety guidance (^[38]). Include a signature or attestation by responsible scientists to reinforce ownership.
• Standardized Structure: Follow the ICH E6 outline so that investigators know where to find information. Table of Contents numbering should remain consistent after versioning for easy reference.
• Integrative Tools: Use spreadsheets or software (like IB-DeRisk) to integrate key parameters (e.g. dose vs effect across species); include simplified charts in the IB if feasible.
• Regulatory Alignment: Align IB language with regulatory guidance updates. For instance, ICH E6(R3) — finalized January 2025 — moved IB content requirements to Appendix A and updated wording (e.g. from “previous human experience” to “previous clinical and nonclinical experience” in overdose guidance) (^[14]). Making sure the IB’s sections follow the latest template can preempt reviewer comments.

Adopting these best practices contributes to the IB’s utility and legitimacy. Ultimately, a well-prepared IB not only satisfies regulations but genuinely enhances trial quality by ensuring that investigators are fully informed.

The Investigator’s Brochure occupies a critical nexus in clinical research: it is both a scientific summary and a safety tool. Our analysis shows that, while the IB is legally mandated, its real-world execution varies widely in quality. Deficits in IB content can impair risk assessment, potentially endangering subjects and undermining research reliability. Conversely, methodological improvements in IB preparation can facilitate innovation by empowering investigators and streamlining regulatory review.

Implications for Stakeholders:

• Sponsors/CROs must recognize the IB as a keystone of trial documentation. Cutting corners in the IB (e.g. delayed updates, truncated reports) can lead to regulatory 483s (inspection notices) or trial holds, which are costly. Investing in IB quality is thus strategically wise. Emerging biotechs, in particular, need to ensure they meet international expectations to avoid setbacks.
• Investigators and Ethics Committees rely on IBs to make critical judgments. They should demand completeness. Institutions might consider requiring specially trained reviewers to independently verify IB content as part of site feasibility or IRB review.
• Regulators could consider more standardized IB evaluation checklists. For example, after Sievers et al.’s study, some regulatory bodies (like the German BfArM) have discussed issuing more detailed IB instructions. The now-finalized ICH E6(R3) guidance (January 2025) is a significant step, and further regional guidelines could emphasize transparency. The MDCG 2024-5 guidance for medical device IBs already provides a detailed checklist approach that could serve as a model for drug IBs as well.
• Patients and Public: Enhanced IB practices align with public trust in trials. When the public hears of tragedies, better IBs (with publicly available summaries) could demonstrate due diligence. Additionally, patient advocacy groups may become involved in pushing for clearer risk communication, bridging the IB and informed consent realms.

Future Directions:

• Digital and Data Integration: The traditional PDF IB may yield to interactive databases. An “e-IB” could allow investigators to query preclinical data on specific endpoints. As medicine moves toward digitalization, linking IB data to electronic consent platforms might enable more up-to-date risk communication. Clinical trial data transparency initiatives (e.g. REWARD Alliance) also push for more open access to preclinical data, potentially changing the IB’s confines.
• Regulatory Evolution: ICH E6(R3) was finalized on January 6, 2025 and places IB content in Appendix A (^[14]). In the EU, the Principles and Annex 1 took effect on July 23, 2025; Annex 2 is scheduled to take effect on January 15, 2027 (^[66]). The guideline addresses current IB development, periodic review, and reference safety information. The FDA Modernization Act 2.0 enacted amendments that permit appropriate nonclinical tests to support investigational use of new drugs. The FDA Modernization Act 3.0, S. 355, passed the Senate in December 2025 but had not become law as of its latest congressional status. It therefore should not be described as an operative FDA requirement or as establishing a deadline to replace animal testing (^[67]).
• Scientific Rigor: The push for reproducibility in science will influence preclinical reporting. Journals and funders increasingly require adherence to good practice in animal studies. ARRIVE 2.0 guidelines remain the standard, and notably, AALAS (American Association for Laboratory Animal Science) journals mandated full ARRIVE 2.0 compliance starting January 2025, including a new manuscript template that ensures all guideline items are addressed (^[68]). As published preclinical data increasingly meet these standards, downstream IBs will inherently improve.
• Global Harmonization: Clinical trials are global. A challenge is that IB requirements are similar but not identical across regions. Initiatives toward single global templates (possibly a companion to ICH E6) might further streamline multinational trials. The EU Clinical Trials Information System (CTIS), fully operational since January 31, 2025 after completing the transition from the old Clinical Trials Directive, was designated a WHO Primary Registry in April 2025, further harmonizing trial data globally. The proposed European Biotech Act (December 2025) aims to reduce initial clinical trial approval timelines from ~106 days to 75 days. For products like combination biologics or novel modalities (gene/cell therapy), IBs are adapting their content (e.g. vector shedding data, GMP manufacturing details). The EMA also issued new guidelines for investigational ATMPs (advanced therapy medicinal products) in July 2025, affecting IB documentation for these complex products (^[69]).
• Digital tools and human oversight: Electronic systems may assist with drafting workflows, controlled distribution, and version tracking. They do not replace sponsor accountability or qualified review of the IB’s accuracy, completeness, balance, and regulatory compliance.
• Advanced Analytics: In the era of “big data,” future IBs might incorporate predictive analytics. For instance, sponsors could run in silico models on combined preclinical/clinical data to anticipate off-target effects, including those not yet seen. With NAMs gaining regulatory acceptance, computational toxicology outputs may increasingly be summarized in IBs to enrich risk assessment. However, the methodology must remain transparent to be accepted.

The Investigator’s Brochure is much more than a regulatory formality: it is the bedrock document ensuring that clinical trials are conducted with full awareness of the investigational product’s profile. Our extensive review shows that the IB’s correct preparation and use are vital for participant safety, ethical integrity, and scientific validity. Regulatorily, an up-to-date, accurate IB is mandated; practically, it empowers investigators to make informed decisions in complex environments.

However, empirical evidence and expert opinion indicate that many IBs need improvement in clarity, completeness, and transparency. Studies finding inadequate reporting of preclinical methods and selective data in IBs (^[6]) (^[3]) are cautionary. Ethically, this gap means that sponsors and investigators may not fully see the potential risks. Conversely, IB-centered tools and guidelines — from IB-DeRisk visualization to AI-powered writing platforms and the now-implemented ICH E6(R3) framework — are actively tackling these issues and refining risk-benefit assessment.

Going forward, sponsors should consider elevating the IB from a compliance checkbox to a strategic communication tool. Technologies enabling interactive IBs, disciplined inclusion of all data, and regular training on IB interpretation could bridge current shortcomings. For regulators and ethicists, encouraging best practices (and possibly auditing IBs more closely) will further protect subjects.

In sum, investing effort in producing a high-quality Investigator’s Brochure matters: it is foundational to the safe progression of medical innovation. When comprehensive and well-structured, the IB truly serves as the “single most comprehensive document summarizing the information on an investigational medicinal product” (^[12]), benefiting all stakeholders and ultimately helping new therapies reach patients safely.